☰

Beryl A. Hatton, Ph.D. - Publications

Affiliations: 
2008 University of Washington, Seattle, Seattle, WA 
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

14 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Hatton BA, Grenley M, Garnsey J, Shinde V, Huszar D, Burns C, Ditzler S, Merrell A, Dey J, Beirne E, Klinghoffer RA. Abstract 4136: Direct intratumoral microdosing via the CIVO® platform reveals anti-tumor immune responses induced by the SUMO inhibitor TAK-981 Cancer Research. 79: 4136-4136. DOI: 10.1158/1538-7445.Am2019-4136  0.654
2015 Kerwin WS, Tretyak I, Grenley MO, You S, Hatton BA, Moreno-Gonzalez A, Thirstrup DJ, Klinghoffer RA. Minimally invasive in tumor multidrug comparative analysis with contrast-enhanced MRI in mice. Magnetic Resonance in Medicine. PMID 26362018 DOI: 10.1002/Mrm.25978  0.508
2015 Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, Morris SM, Watts KL, Veiseh M, Grenley MO, Tretyak I, et al. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Science Translational Medicine. 7: 284ra58. PMID 25904742 DOI: 10.1126/Scitranslmed.Aaa7489  0.688
2015 Klinghoffer R, Moreno-Gonzalez A, Carleton M, Grenley M, Hatton B, Frazier J, Kerwin W, Tretyak I, Hedin N, Dey J, Casalini J, Ditzler S, Olson J, Caffo N. Abstract A39: A platform to assess multiple therapy options simultaneously in a patient's own tumor Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-A39  0.667
2014 Klinghoffer R, Moreno-Gonzalez A, Carleton M, Frazier J, Grenley M, Tretyak I, Hedin N, Dey J, Casalini J, Hatton B, Ditzler S, Olson J, Pierce D, Filvaroff E, Caffo N. Abstract 3129: A platform to assess multiple therapy options simultaneously in a patient's own tumor Cancer Research. 74: 3129-3129. DOI: 10.1158/1538-7445.Am2014-3129  0.673
2013 Hatton BA, Ellison DW, Gajjar A, Kool M, Fero M, Olson JM. Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma. Biomarker Research. 1: 14. PMID 24252239 DOI: 10.1186/2050-7771-1-14  0.605
2013 Hatton BA, Grenley M, Hedin N, Caffo N, Hyer ML, Manfredi M, Blakemore S, Klinghoffer RA, Bence N. Abstract 4153: Arrayed microinjection of a ubiquitin activating enzyme inhibitor induces PD biomarker effects predictive ofin vivotumor responses to systemic drug delivery. Cancer Research. 73: 4153-4153. DOI: 10.1158/1538-7445.Am2013-4153  0.602
2012 Dey J, Ditzler S, Knoblaugh SE, Hatton BA, Schelter JM, Cleary MA, Mecham B, Rorke-Adams LB, Olson JM. A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Molecular and Cellular Biology. 32: 4104-15. PMID 22869526 DOI: 10.1128/Mcb.00862-12  0.592
2012 Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, LeBlanc M, Randolph-Habecker J, Knoblaugh SE, Hansen S, Richards A, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proceedings of the National Academy of Sciences of the United States of America. 109: 7859-64. PMID 22550175 DOI: 10.1073/Pnas.1114718109  0.696
2010 Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, Ditzler S, Pullar B, Stroud MR, Olson JM. Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene. 29: 3865-72. PMID 20440271 DOI: 10.1038/Onc.2010.142  0.555
2008 Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, Hansen S, Knoblaugh SE, Lee D, Eberhart CG, Hallahan AR, Olson JM. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Research. 68: 1768-76. PMID 18339857 DOI: 10.1158/0008-5472.Can-07-5092  0.634
2006 Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alborán IM, Olson JM, Eisenman RN. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Research. 66: 8655-61. PMID 16951180 DOI: 10.1158/0008-5472.Can-06-1621  0.469
2006 Hatton BA, Pritchard JI, Olson JM. Nervous system cancer models: Medulloblastoma Drug Discovery Today: Disease Models. 3: 167-174. DOI: 10.1016/J.Ddmod.2006.05.007  0.574
2004 Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID, Beachy PA, Olson JM. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Research. 64: 7794-800. PMID 15520185 DOI: 10.1158/0008-5472.Can-04-1813  0.642
Show low-probability matches.